Full-length LRH-1 structural regulation

全长LRH-1结构调整

基本信息

批准号：
10034145
负责人：
Raymond Daniel Blind
金额：
$ 34.6万
依托单位：
VANDERBILT UNIVERSITY MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-01 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10034145
关键词：
Address Affect Affinity Agonist Amino Acids Architecture Benzophenones Bile Acids Binding Biophysics Chemicals Cholesterol Cholesterol Homeostasis Clinic Clinical Communication Computer Models Cryoelectron Microscopy Crystallography DNA DNA Binding Domain Data Development Drug Design Drug Targeting Event Gene Expression Profiling Gene Expression Regulation Genes Genetic Transcription Glucose Hepatocyte Human Hydrophobicity Individual Knockout Mice Length Ligand Binding Ligand Binding Domain Ligands Liver Metabolic Modeling Molecular Mus Mutation NR5A2 gene Non-Insulin-Dependent Diabetes Mellitus Nuclear Nuclear Receptors Oranges Patients Peptides Pharmaceutical Preparations Pharmacology Physiological Physiology Positioning Attribute Post-Translational Protein Processing Regulation Resolution Structural Models Structure Structure-Activity Relationship System Testing Therapeutic Treatment Efficacy base biophysical analysis biophysical techniques blood glucose regulation cohesion crosslink cysteinylcysteine drug development experience flexibility insight liver metabolism mouse model mutant nanomolar non-alcoholic fatty liver disease nonalcoholic steatohepatitis optimism pre-clinical prevent receptor function recruit response simulation small molecule structural biology tool

项目摘要

LRH-1 (NR5A2) is a monomeric nuclear receptor involved in many aspects of liver physiology, including bile acid, cholesterol and glucose homeostasis. LRH-1 activation has beneficial effects on liver metabolism in pre-clinical mouse models. As nuclear receptors like LRH-1 have a very druggable ligand-binding pocket, LRH-1 has been targeted by many drug development efforts with great recent progress, however an LRH-1 agonist is still not available in the clinic. Like most other nuclear receptors, LRH-1 is composed of a DNA-binding domain and a ligand-binding domain, which are connected by a large unstructured Hinge domain. Classic nuclear receptor drug design has focused on the isolated ligand-binding domain, as the regulatory mechanism of this isolated domain is very well understood at the molecular level: binding of a hydrophobic small molecule allosterically alters ligand-binding domain recruitment of a transcriptional coregulator, which regulates nuclear receptor function. However, several lines of evidence suggest inter-domain communication exists between LRH-1 domains, regulating function. Understanding the structural biology behind this inter-domain communication might help LRH-1 drug design efforts, however technical challenges in applying crystallography or cryo-EM has prevented progress, despite great effort from several groups. We used an integrated structural approach to develop a low-resolution, but high confidence model of the intact, full-length LRH-1, using exclusively solution-based biophysical analyses and computational modeling (HDX, SAXS, chemical crosslinking, artificial amino acid benzophenone cross linking, Cys-Cys interdomain crosslinking, Rosetta and MD simulations). The model explains human patient mutations and structure-based mutations predicted to reside in the interface between the domains, which we show alter full length LRH-1 structure and function. Here, we propose to take advantage of this solution-based approach to address several long-standing questions in the field: Aim 1 determines how various ligands change full length LRH-1 interdomain communication. Aim 2 resolves how the SUMO module post-translational modification alters LRH-1 interdomain communication. Aim 3 identifies the genes effected by structure-based LRH-1 mutations in mouse liver and primary hepatocytes. Our current understanding of how LRH-1 structure is regulated is limited to studies of the individual domains. Without understanding how full-length LRH-1 is regulated, we cannot know if our current drug design efforts are taking full advantage of the entire therapeutic capacity of LRH-1.

LRH-1（NR5A2）是一种参与肝脏生理多个方面的单体核受体，包括胆汁酸，胆固醇和葡萄糖稳态。 LRH-1激活对临床前小鼠模型中的肝脏代谢具有有益作用。由于像LRH-1这样的核受体具有非常可吸毒的配体结合口袋，因此LRH-1受到许多药物开发工作的针对性，最近进展取得了长足的进步，但是LRH-1激动剂仍未在诊所中使用。与大多数其他核受体一样，LRH-1由DNA结合结构域和配体结合结构域组成，该结构域通过大型非结构化铰链结构域连接。经典的核受体药物设计集中在孤立的配体结合结构域上，因为该孤立结构域的调节机制在分子水平上非常了解：疏水性小分子的结合变化了配体结合结构域的转录核心构建物，从而调节了核受体功能。但是，几条证据表明，LRH-1域之间存在域间的交流，调节功能。了解这种域间交流背后的结构生物学可能有助于LRH-1药物设计工作，但是尽管有几个小组的努力，尽管采用晶体学或冷冻EM的技术挑战仍阻止了进步。我们使用了一种完整的完整，全长LRH-1的综合结构方法，使用完全基于解决方案的生物物理分析和计算建模（HDX，SAXS，化学交联，人造氨基酸苯甲酸苯甲酮交叉链接，Cys-cys-cys-cys-cys-cys-cross interdomain intermain，RoseTTA和Mimaintion）。该模型解释了人类患者突变和基于结构的突变，预计将驻留在域之间的界面中，我们显示了全长的LRH-1结构和功能。在这里，我们建议利用这种基于解决方案的方法来解决该领域的几个长期问题：AIM 1确定各种配体如何改变全长LRH-1 Interydomain交流。 AIM 2解决了SUMO模块的翻译后修饰如何改变LRH-1 Interdomain通信。 AIM 3识别小鼠肝脏和原发性肝细胞中基于结构的LRH-1突变影响的基因。我们目前对LRH-1结构如何调节的理解仅限于对单个领域的研究。在不了解全长LRH-1的调节方式的情况下，我们不知道我们当前的药物设计工作是否充分利用了LRH-1的整个治疗能力。